biostudies-literatureCalifano DUniversity of Campania "Luigi Vanvitelli"Ministero della SaluteMinistero degli Affari EsteriUniversity of Campania &quot;Luigi Vanvitelli&quot;Italian Association for Cancer ResearchAssociazione Italiana Di Oncologia Medica5152https://www.ebi.ac.uk/biostudies/studies/S-EPMC8533892biostudies-literatureUnknown13(20)<h4>Background</h4>Epithelial ovarian cancer (EOC) is a rare, highly lethal disease. In a subset of high grade EOC patients, maintenance therapy with the antiangiogenic drug Bevacizumab (BEV) is a valuable option. To date, no validated predictive or prognostic biomarkers exist for selecting EOC patients that might benefit from BEV treatment.<h4>Methods</h4>Immunohistochemistry and RT-qPCR evaluated the expression of seven angiogenesis-related proteins and of a twelve microRNAs angio-signature in EOC patients, treated in first line with chemotherapy plus BEV (MITO16A/ManGO OV-2 phase IV trial). Centralized statistical analyses assessed the associations between each biomarker, clinical prognostic factors and survival outcomes.<h4>Results</h4>High miR-484 expression was associated with longerCancersEvaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study.PMC8533892To S.P.CRO Ricerca Corrente grant (linea 1)RCR-2019-23669115PGR01230IRCCS-G. Pascale Ricerca Corrente grant M2/7Programma VALERE20902RF-2016-02361040Russo DCitron FPerrone FMontella MBignotti EGargiulo PZannoni GFSignoriello SChiodini PSimeon VScambia GLosito NSBaldassarre GScognamiglio GGallo DDe Cecio RSpina ACanzonieri VRampioni Vinciguerra GLPignata SCecere SCSchettino CFerrandina GPiccirillo MCTognon GDel Sesto MCalifano DArenare LColombo NCiucci AfalseEvaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study.<h4>Background</h4>Epithelial ovarian cancer (EOC) is a rare, highly lethal disease. In a subset of high grade EOC patients, maintenance therapy with the antiangiogenic drug Bevacizumab (BEV) is a valuable option. To date, no validated predictive or prognostic biomarkers exist for selecting EOC patients that might benefit from BEV treatment.<h4>Methods</h4>Immunohistochemistry and RT-qPCR evaluated the expression of seven angiogenesis-related proteins and of a twelve microRNAs angio-signature in EOC patients, treated in first line with chemotherapy plus BEV (MITO16A/ManGO OV-2 phase IV trial). Centralized statistical analyses assessed the associations between each biomarker, clinical prognostic factors and survival outcomes.<h4>Results</h4>High miR-484 expression was associated with longer2021-01-01T00:00:00Z2021 Oct2026-04-08T06:49:01.614Z2025-02-19T03:53:15.16ZS-EPMC85338923468030110.3390/cancers13205152